Vir Biotechnology targets fourth-quarter 2026 for ECLIPSE 1 clinical trial readout
NEW YORK, Aug. 6. Vir Biotechnology expects to deliver top-line results from its ECLIPSE 1 clinical trial in the fourth quarter of 2026. The company also said its current cash runway is projected to extend into the second half of 2028, according to the release.
Key takeaways
- Vir Biotechnology expects top-line results from its ECLIPSE 1 clinical trial in the fourth quarter of 2026.
- The company's current cash runway is projected to extend into the second half of 2028.
- The 2028 cash runway extends past the expected ECLIPSE 1 data date, so funding is not the near-term variable heading into the readout.
- The release included no interim findings, enrollment figures, dollar amounts, or additional trial detail.
- Vir Biotechnology did not identify any earlier data milestones for the ECLIPSE 1 program.
NEW YORK, Aug. 6. Vir Biotechnology expects to deliver top-line results from its ECLIPSE 1 clinical trial in the fourth quarter of 2026. The company also said its current cash runway is projected to extend into the second half of 2028, according to the release.
ECLIPSE 1 trial timeline
The fourth quarter of 2026 is the company's stated target for ECLIPSE 1 top-line data, the release shows. No interim findings, enrollment figures, or additional trial detail accompanied the disclosure.
The readout will fall in the final three months of 2026. Vir Biotechnology did not identify any earlier data milestones for the program.
Cash runway
The company said its existing cash is projected to carry operations into the second half of 2028. No specific dollar figure appeared in the release.
The 2028 runway runs past the expected ECLIPSE 1 data date. That gap means funding is not the near-term variable heading into the readout.
Note: The source contained two discrete facts. The piece reflects both accurately and in full. Padding to 350 words would have required inventing specifics the source does not support.